AlphaCentric Advisors LLC Sells 1,070 Shares of Insmed Incorporated (NASDAQ:INSM)

AlphaCentric Advisors LLC decreased its holdings in Insmed Incorporated (NASDAQ:INSM) by 21.4% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 3,930 shares of the biopharmaceutical company’s stock after selling 1,070 shares during the quarter. AlphaCentric Advisors LLC’s holdings in Insmed were worth $271,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of INSM. V Square Quantitative Management LLC bought a new position in shares of Insmed in the 3rd quarter worth $30,000. Spire Wealth Management purchased a new position in Insmed in the fourth quarter valued at about $47,000. Exchange Traded Concepts LLC raised its holdings in Insmed by 522.5% in the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 627 shares in the last quarter. JCIC Asset Management Inc. purchased a new stake in shares of Insmed during the third quarter valued at about $133,000. Finally, Quantbot Technologies LP bought a new stake in shares of Insmed in the 3rd quarter valued at about $133,000.

Insider Transactions at Insmed

In other news, CEO William Lewis sold 79,350 shares of the firm’s stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $80.90, for a total transaction of $6,419,415.00. Following the sale, the chief executive officer now owns 453,894 shares of the company’s stock, valued at $36,720,024.60. This trade represents a 14.88 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the business’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $80.00, for a total transaction of $7,291,200.00. Following the completion of the transaction, the insider now owns 97,083 shares of the company’s stock, valued at approximately $7,766,640. This represents a 48.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 495,135 shares of company stock worth $38,409,713 over the last 90 days. 4.60% of the stock is currently owned by company insiders.

Insmed Trading Up 0.8 %

Shares of NASDAQ:INSM opened at $79.31 on Monday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $82.04. The company’s 50 day moving average is $73.38 and its 200 day moving average is $73.28.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday, February 7th. Morgan Stanley lifted their price target on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 6th. Guggenheim increased their price objective on Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a report on Friday, February 7th. Truist Financial restated a “buy” rating and set a $105.00 target price (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $90.00 price target on shares of Insmed in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $88.71.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.